References
- Coveñas R, Muñoz M. Cancer progression and substance P. Histol Histopathol. 2014 Jul;29(7):881–890.
- Javid H, Mohammadi F, Zahiri E, et al. The emerging role of substance P/neurokinin-1 receptor signaling pathways in growth and development of tumor cells. J Physiol Biochem. 2019;75(4):415–421. DOI:10.1007/s13105-019-00697-1.
- Chen XY, Ru GZ, Ma YY, et al. High expression of substance P and its receptor neurokinin-1 receptor in colorectal cancer is associated with tumor progression and prognosis. Onco Targets Ther. 2016 June 16;9:3595–3602. DOI:10.2147/OTT.S102356.
- Ma J, Yuan S, Cheng J, et al. Substance P promotes the progression of endometrial adenocarcinoma. Int J Gynecol Cancer. 2016;26(5):845–850. DOI:10.1097/IGC.0000000000000683.
- Nowicki M, Ostalska-Nowicka D, Konwerska A, et al. The predicting role of substance P in the neoplastic transformation of the hypoplastic bone marrow. J Clin Pathol. 2006;59(9):935–941. DOI:10.1136/jcp.2005.034629.
- Ambalavanar R, Moritani M, Moutanni A, et al. Deep tissue inflammation upregulates neuropeptides and evokes nociceptive behaviors which are modulated by a neuropeptide antagonist. Pain. 2006 Jan;120(1–2):53–68. DOI:10.1016/j.pain.2005.10.003.
- Harrison S, Geppetti P. Substance P. Int J Biochem Cell Biol. 2001 Jun;33(6):555–576.
- Corruccini RS. How anthropology informs the orthodontic diagnosis of malocclusion’s causes. Lewiston (NY): Edwin Mellen Press; 1999. p. 1–16.
- Gamse R. Physiology and physiopathology of substance P. Arzneimittelforschung. 1984;34(9A):1074–1079.
- Durham P. Gene-related peptide (CGRP) and migraine. Headache. 2006 June;46(Suppl 1):S3–S8.
- White BA, Williams LA, Leben JR. Health care utilization and cost among health maintenance organization members with temporomandibular disorders. J Orofac Pain. 2001 Spring;15(2):158–169.
- Shimshak DG, Kent RL, DeFuria M. Medical claims profiles of subjects with temporomandibular joint disorders. CRANIO®. 1997 Apr;15(2):150–158.
- Traub RJ, Cao DY, Karpowicz J, et al. A clinically relevant animal model of temporomandibular disorder and irritable bowel syndrome comorbidity. J Pain. 2014 Sep;15(9):956–966. DOI:10.1016/j.jpain.2014.06.008.
- Michaud DS, Fu Z, Shi J, et al. Periodontal disease, tooth loss, and cancer risk. Epidemiol Rev. 2017 Jan 1;39(1):49–58.
- Muñoz M, Crespo JC, Crespo JP, et al. Neurokinin-1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: A case report. Clin Oncol. 2019 Jul;11(1):50–54.
- Muñoz M, Rosso M, Coveñas R. Neurokinin-1 Receptor antagonists against hepatoblastoma. Cancers (Basel). 2019 Aug 28;11(9):pii:E1258.